Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2) - Concepedia

Concepedia

Publication | Open Access

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

DOI Full Paper Access

29

Citations

40

References

2023

Year

Roy Fleischmann, Désirée van der Heijde, Vibeke Strand, Tatsuya Atsumi, Iain B. McInnes, Tsutomu Takeuchi, Peter C. Taylor, Marguerite Bracher, David P. Brooks, John Davies,

Annals of the Rheumatic Diseases

Abstract

NCT03980483, NCT03970837.

References

	Year	Citations

Page 1